SmartTRAK identified several trends at NASS 2022 that have the potential to improve patient care and drive advancement in the spine market, including the shift of fusion procedures to the ASC setting, a potential tipping point for the adoption of endoscopic spine care, and emerging innovations within the interbody space.

At the North American Spine Society (NASS) 2022 Annual Meeting in Chicago, SmartTRAK witnessed a revival in energy that has been absent in recent years due to COVID-19, healthcare disruption and industry M&A integration. Exhibitors had the opportunity to teach attendees about new technology in a multitude of ways – a new live surgical theater was proudly projected throughout the exhibit hall and most companies were equally inviting to conversations about macro technology developments. Though SmartTRAK has seen so much innovation in spine over the recent several years, which of these advancements will truly lead to improved patient care? SmartTRAK identified several trends at NASS 2022 that have the potential to improve patient care and drive growth in the spine market over the coming two-to-five years. These include the shift of procedures from the hospital to outpatient and ambulatory surgery center (ASC) settings, increased adoption and adaptation within surgical approaches and the introduction of custom interbody implants, and many others.

Among the many topics covered in detail in this article are:

Observations and analysis from the 37th Annual North American Spine Society (NASS) Meeting held October 12-14 in Chicago, IL. 

SmartTRAK highlights the top news and themes at NASS 2022 affecting the markets for OrthoBio and Regenerative Medicine, including the Orthofix/SeaSpine  merger, the ongoing controversy surrounding BMP-2, new product launches, company growth strategies and the latest research and innovation in intradiscal therapies.

Among the many topics covered in detail in this article are:

• A Spine Merger That Will Significantly Impact The Orthobiologics Landscape
• BMP-2 Safety Profile Remains an Open Issue
• Incremental Product Improvement Across OrthoBio Categories
• Spine Strategic Portfolio Strategies
• Intradiscal Treatments Take Center Stage

Undoubtedly, the proposed business combination of Orthofix and SeaSpine announced immediately prior to NASS was the most impactful news emanating from the meeting. On a proforma basis, the combined company is expected to generate approximately ...

To download and read the complete "OrthoBio-Focused Themes Emerging from NASS 2022" article by James Petricek,  SmartTRAK's GM, OrthoBio and Regenerative Medicine, just click the button below.

SmartTRAK is pleased to announce that Linda Bernier has been named new Chief Growth Officer (CGO). Linda will oversee Sales, Customer Success and Marketing. She will be involved with projects ranging from customer retention and satisfaction, licensing new tools and data sources, new products and strategy, marketing and new messaging, among others. She comes with a depth of experience in the healthcare and SaaS world, having held CEO and Chief Marketing Officer positions during her career

"Linda has great leadership and interpersonal skills (positivity, woo and communication are among her top strengths), and she likes to put ideas into action and get things done (achiever and strategic also in her top 5). Above all, she brings the experience, knowledge and confidence we have needed to successfully make the pivot to becoming a SaaS company with our new SmartTRAK Enterprise offering." SmartTRAK CEO Sharon O'Reilly

Meet Linda Bernier, SmartTRAK's new Chief Growth Officer:

What is your role with SmartTRAK? As Chief Growth Officer, my main objectives are to execute our founder and CEO Sharon O’Reilly’s vision for SmartTRAK and to achieve the company’s full potential as the leading market insights solution for the MedTech industry. In my role, I’ll be working with the sales, marketing and customer success teams to execute key initiatives to profitably grow the company. These initiatives include increasing client engagement, continuing our stellar > 95% retention rate through voice of client, acquiring new clients, elevating the SmartTRAK brand and expanding SmartTRAK’s portfolio of products and services, including the potential entry into new markets.
 
What do you like about SmartTRAK? When I listen to customers, they consistently say SmartTRAK is their trusted source for

In the market for Total Joint Replacement, companies continue to innovate with assistive technologies and new implants and instruments to advance clinical outcomes and increase efficiency of care. From new hip products optimized for the direct anterior approach to cementless knee solutions, companies are focusing on technologies that provide optimal outcomes whether surgeries are performed in a hospital, hospital outpatient or ASC setting. The following is a sample of SmartTRAK's recent Total Joints news and developments from around the world, compiled, curated and posted in real time by the expert analysts at SmartTRAK.

We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more. Our users think it's the perfect way to start their day.

New Products:

• JNJ/DePuy Synthes*
  

  JNJ/DePuy Synthes did not discuss its new EMPHASYS hip implants during its Q322 earnings call. However, SmartTRAK would not be surprised to see the Company introduce the system at AAHKS 2022 with the EMPHASYS Cup* recently receiving 510(k) clearance to round out the platform.

• Exactech*

  Exactech announced the successful first surgeries and limited launch of the Novel Total Hip Arthroplasty System with the Spartan Stem* and Logical Cup* with full commercial US launch planned for H123. Exactech is a distributor of the implants supplied by Signature Orthopaedics*.

OFIX and SPNE announced a definitive agreement to combine in an all-stock merger of equals. Both companies believe there are meaninful cross-selling revenue synergies, as well as at least $40MM in YoY cost savings to capture over the 3 years following the transaction. The companies have expressed revenue goals of ~$1.0B concluding year 3 post-merger.

Looking forward, the new organization will be a spine and orthopedics company with complementary portfolios in biologics, spinal hardware, bone growth therapies, orthopedic solutions and enabling surgical technologies. SmartTRAK notes that once merged, the new company will be strategically positioned in high-growth emerging technology, including cervical disc replacement with M6-C, enabling technology with 7D’s FLASH Navigation System and OrthoNext preop planning, and with focused development in spine and limb within pediatrics. Additionally, the new company will have a highly competitive offering in the spinal interbody space with its WaveForm 3D and NanoMetalene technologies. Together, the combined company’s biologics portfolio will also represent one of the broadest offerings available in spine and orthopedics.

SmartTRAK believes the complimentary product portfolios provide a comprehensive offering and

 In an interview with SmartTRAK, Joel Gambrell, Co-founder and CEO for Astura Medical, shares the series of new products launching at NASS and, specifically, reveals what makes Astura’s new Integrated Expandable ALIF System, El Capitan, truly differentiated.

Since the Company was founded in 2014, Astura Medical has achieved fast growth, established a reputation for elegance and quality in its product offering and taken a different methodology to both product development and business operations. In an interview with SmartTRAK, Joel Gambrell, Co-founder and CEO, provides insight on how Astura’s R&D process is unique, unveils why Astura’s approach to custom implants offers the most real-time precision and reveals the distinctions that make the new Integrated Expandable ALIF System, El Capitan, truly differentiated. In addition to El Capitan, Astura Medical will be launching several other new technologies at the North American Spine Society’s (NASS) annual 2022 meeting in Chicago. 

SmartTRAK's spine experts will be roaming the floor at NASS 2022, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest news and innovations in the Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.  If you would like to book a meeting with us at NASS, just click here.

Continue reading to find out how to download a complete transcript of SmartTRAK's interview with CEO Joel Gambrell.

With the North American Spine Society (NASS) 2022 annual meeting next week in Chicago, anticipation builds to see if some of the top players' product launches are unveiled at the event, including potential new offerings from Medtronic and NuVasive. Meanwhile, SmartTRAK expects to see bright spots from some of the pure-play companies like Centinel, Alphatec and Astura Medical. The event will surely be a pick-me-up from sluggish market performance plagued by budget constraints and supply chain issues. 

Our spine experts will be roaming the floor, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest in the spine market and discuss how SmartTRAK can help you Be the Expert in your market. To make sure you’re up to speed before the meeting, here is a sample of recent spine news collected and curated by the expert analysts at SmartTRAK. If you would like to book a meeting with us at NASS, please click the button below.

New Products:

• prodisc C* - Centinel Spine*
  

  Centinel Spine announced expansion of the prodisc cTDR portfolio. Currently, Centinel has 510(k) clearance for 1-level indications for prodisc C Vivo, prodisc C SK and prodisc C Nova giving them the broadest global offering in cTDR.

Spine enabling tech companies continue to report positive momentum moving into H222 despite limited hospital budgets, chip shortages and continued staffing issues. The North American Spine Society (NASS) 2022 annual meeting next week is sure to provide a preview of what is coming next for both spine robotics from players like Medtronic and Globus, as well as surgical guidance solution providers such as NuVasive and SeaSpine. We are also looking forward to new enabling tech solutions to be launched at the meeting.

Our spine experts will be roaming the floor, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest in the CAS Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.

To make sure you’re up to speed before the meeting, here is a sample of recent CAS Spine news collected and curated by the expert analysts at SmartTRAK. If you would like to book a meeting with us at NASS, please click the button below. New Products:

• Stryker*
  

  SYK announced the launch of its Q Guidance System for spine applications, which includes surgical planning and intra-op guidance for spine procedures in patients age 13 and older.